CMC, and labelling, related to its area.

Function-Centric Model: Teams are structured around regulatory specialties or operational tasks—such as CMC (Chemistry, Manufacturing & Controls), labelling, regulatory intelligence, or lifecycle management. Each function services all therapeutic areas with their subject matter expertise.

The choice between these models—often influenced by portfolio size, geographic spread, and internal expertise—affects interactions with regulatory agencies, the depth of team knowledge, and overall global regulatory governance. Large multinational sponsors may even leverage hybrid models, integrating aspects of both to tailor their regulatory approach.

This article explores the documentation, regulatory expectations, and inspection considerations for both TA and function-based RA structures. Special attention is paid to ICH Q10 (Pharmaceutical Quality System) and Q12 (Lifecycle Management), as well as agency-specific requirements from FDA (FDA Drugs), EMA, and MHRA. Furthermore, we highlight how expert pharma regulatory consultants can help optimise these operating models to meet the evolving expectations of global regulators.

Frameworks and Regulatory Expectations: US, UK, and EU

Across jurisdictions, regulatory authorities share core expectations regarding infrastructure and processes for RA teams, regardless of their organisational structure. The way RA functions are organised must support regulatory compliance throughout:

• Initial product development
• Clinical trial authorisations
• Marketing authorisation submissions
• Post-approval lifecycle management (variations, renewals, safety updates)

US FDA (21 CFR 314, 21 CFR 312): The FDA expects clear, documented responsibility matrices—whether by TA or function—for preparation and submission of Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and post-marketing supplements. Organisational accountability, traceability, and documentation flow are essential, and are reviewed during pre-approval and surveillance inspections. According to 21 CFR 314, sponsors must define roles in application preparation, adverse event reporting, and label updates.

EMA (Regulation (EC) No 726/2004, CHMP Guidance): The EMA highlights the necessity for efficient communications across Member States, robust coordination of cross-functional tasks (especially for centralised procedures), and subject matter expertise relevant to both TA and product lifecycle. The Common Technical Document (CTD) guidance requires clear task assignments in Module 1 (Administrative Information) and throughout the submission dossier.

MHRA (UK): The MHRA aligns with EU expectations post-Brexit and emphasises technically robust and auditable RA processes. The guidance for licence applications necessitates clarity in team accountability, data stewardship, and local context adaptation—especially for labelling and pharmacovigilance.

ICH Q10, Q12: Global standards under ICH Q10 (effective pharmaceutical quality systems) and ICH Q12 (product lifecycle management) reinforce the expectation that RA governance—through either TA or function orientation—provides documented responsibility, management review, and knowledge management. ICH guidelines focus on the seamless flow of regulatory information, the integration of RA with quality and clinical functions, and transparent change management sites.

Pharma regulatory consultants typically advise that neither model is inherently superior—rather, the chosen model must be demonstrably adequate to meet the expectations of all relevant health authorities and must be mapped to enable readiness for regulatory inspections, cross-functional integration, and rapid response to queries or deficiencies.

Documentation Requirements and Practical Considerations

A robust regulatory affairs operating model is underpinned by a comprehensive set of documentation and procedural controls. These span both global operating procedures and country-level work instructions, and must explicitly state how RA activities are managed and decisions documented, particularly when responsibilities are distributed by therapeutic area or function.

Organisational Documentation Essentials

• Responsibility Matrix (RACI): A clearly articulated RACI chart detailing stakeholders for each submission element (Module 1–5 for CTD/eCTD). For TA models, responsibilities are mapped by portfolio; for function-based models, by discipline (e.g., CMC, Labelling).
• Global RA Procedures: Standard Operating Procedures (SOPs) outlining end-to-end regulatory lifecycle management, including pre-submission meetings, data gathering, review, and submission protocols. SOPs must comply with 21 CFR 11, EU GMP Annex 11, and local GxP regulations.
• Submission Planning & Tracking: Detailed plans and digital tools (like regulatory information management systems, or RIMS) that capture status across regions and flag dependencies, such as Module 3 CMC updates or label harmonisation for global products.
• Regulatory Intelligence Logs: Continuous monitoring and documentation of regulatory developments by region, therapeutic area, and function. Pharma regulatory consultants advise keeping records of applicable guideline updates and health authority communications to inform submission strategy and risk assessment.
• Change Control and Variation Management: Documentation describing how post-approval changes are identified, evaluated, and implemented in accordance with ICH Q12, EU Variation Regulation (EC) No 1234/2008, and FDA requirements for supplements and annual reports.
• Agency Contact Records: Traceable communications with FDA, EMA, MHRA, including formal advice, requests for information, and inspection outcomes. Tracking by TA or function enables accountability and trend analysis.

Key Challenges in Documentation

• Gaps in Ownership Clarity: Agencies may raise deficiencies if SOPs fail to make clear which team or individual is accountable for specific filings, especially at the interface of multiple therapeutic areas or cross-functional processes.
• Version Control: Failure to align global and regional documentation repositories can lead to uncontrolled local procedures diverging from group RA policy.
• Lack of Audit Trails: Health authorities increasingly request evidence of decision-making, document history, and change justifications—critical for both functional and TA-aligned RA structures.

Pharma regulatory consultants recommend routine gap assessments and documentation audits to ensure ongoing compliance and inspection readiness. Electronic document management systems (EDMS) are valuable for elevating control standards and enabling rapid responses to regulatory queries and third-party audits.

Inspection Expectations: Demonstrating Robust RA Governance

Regulatory inspections increasingly evaluate not only the content of submissions but the underlying organisation and governance of RA teams. Whether a company has opted for a therapeutic-area or functional model—or a blend—inspectors probe the demonstration of sustained compliance, clear roles and accountability, and effective knowledge transfer. Both FDA and EU regulators have clarified that inadequate or unclearly delineated RA structures are a recurrent inspection deficiency.

US FDA Inspection Focal Points

• Submissions Ownership: Inspectors may request demonstration of author, reviewer, and approver assignments for INDs, NDAs, supplements, and communications—demanding transparency whether by TA or function.
• Procedural Alignment: FDA’s focus on the integration of RA with quality and safety functions (as per 21 CFR 314 and 21 CFR 600-series for biologics) demands documentation of cross-functional review and signoff, which must be auditable under either RA model.
• Continuous Improvement: Evidence of management review, routine self-inspections, and training for both functional and TA-based teams is expected to demonstrate compliance with ICH Q10 and FDA’s Quality Systems Guidance.

EMA and MHRA Inspection Focus

• Global-Regional-Local Integration: EMA and MHRA inspections regularly review the harmonisation of global and national processes—especially regarding labelling, PSUR/DSUR submissions, and product variations—to ensure consistent regulatory messaging and timely implementation of safety updates.
• Knowledge Management: According to ICH Q12 and EMA Reflection Papers, evidence of systematic knowledge capture and transfer between TAs or functions is key for successful lifecycle management and regulatory resilience.
• Regulatory Intelligence and Implementation: Inspectors expect to see robust mechanisms for the uptake of new guidelines and regulatory requirements (e.g., new templates for centralised submissions or Brexit-driven procedural changes), covering both TA specialists and functional leads.

Common deficiencies cited by agencies include:

• Ambiguities in SOPs regarding the delineation of submission responsibility, leading to missed deadlines or inconsistent messaging across regional authorities
• Poor documentation of internal regulatory advice, such as the scientific rationale for submission strategies or the handling of regulatory authority feedback
• Failure to track and report deviations from planned regulatory strategies (e.g., unexpected CMC changes or labelling inconsistencies not escalated to oversight committees)

To address these risks, pharma regulatory consultants often facilitate mock inspections or pre-inspection gap analyses, benchmarking RA team organisation, training, and documentation workflows against global standards. Investment in continuous training—aligned to evolving FDA, EMA, and MHRA requirements—positions companies for more robust inspection outcomes regardless of the RA structural model chosen.

Strategic Considerations: Selecting and Optimising Your Operating Model

Deciding whether to organise RA teams around therapeutic areas, functions, or a hybrid involves a complex blend of regulatory, operational, and strategic factors. For sponsors seeking support, pharma regulatory consultants help organisations balance efficiency, depth of expertise, and compliance agility.

Advantages and Challenges of Therapeutic Area (TA)-Centric RA Models

• Strengths: Teams gain deep disease-specific knowledge, tailoring regulatory strategies to unique scientific and market access nuances. Close integration with R&D allows earlier identification of regulatory hurdles. Streamlined regulatory communication with agencies is possible for complex, fast-evolving therapeutic landscapes (e.g., oncology).
• Drawbacks: Risk of duplication in functional expertise (multiple TAs developing separate CMC or labelling standards); potentially harder to maintain global harmonisation when teams work in siloes; challenge in ensuring rapid regulatory intelligence uptake across all TAs.

Advantages and Challenges of Function-Centric RA Models

• Strengths: Fosters development of deep technical expertise in core disciplines (e.g., CMC, labelling, regulatory intelligence). Supports global harmonisation, centralised training, and efficient use of resources for standard processes. Consistent regulatory messaging and easier adoption of new guidance (e.g., changes in electronic submission requirements).
• Drawbacks: Risk of insufficient disease-area context affecting regulatory strategy and submissions. Potential for misaligned priorities across functions and therapeutic priorities, and slower escalation of issues that require integrated TA insight.

Hybrid and Matrix Models are increasingly common, combining TA leads with function-specific subject matter experts. For instance, an oncology RA lead partners with global CMC, safety, or labelling experts. This model can offer the benefits of both depth and technical breadth, but requires robust coordination, clear governance, and sophisticated documentation systems.

Best Practices for Effective RA Operating Model Implementation:

1. Establish a documented governance structure outlining decision-making authorities by TA and function
2. Maintain flexible, risk-based SOPs that accommodate both local regulatory nuances and global harmonisation needs
3. Invest in regulatory information management technology that enables transparent workflows, role-based access, and version history tracking
4. Ensure ongoing training on evolving regional/global requirements, ICH guidelines, and inspection expectations for all RA staff
5. Conduct regular reviews of RA operating model effectiveness, leveraging feedback from regulatory authority interactions and inspections
6. Engage external pharma regulatory consultants for targeted operational or compliance projects, such as pre-inspection readiness, policy harmonisation, or change management during mergers/acquisitions

To stay at the forefront of global regulatory governance, pharma regulatory affairs leaders must approach operating model design as a living process, subject to periodic review and agile adaptation. Regulatory agencies increasingly focus on governance transparency, decision traceability, and integrated knowledge management—demands which must be met regardless of organisational shape.

Conclusion: Tailoring Regulatory Affairs Foundations for Future Regulatory Success

As products grow more scientifically complex and regulatory expectations intensify across the US, UK, and EU, the organisational design of regulatory affairs teams is more than an operational choice—it is a foundation for compliant, responsive, and strategic product development and lifecycle management. Whether implemented by therapeutic area or function, or as a hybrid, the RA operating model must be defensible, documented, and demonstrably effective in supporting regulatory compliance and product safety.

Global regulatory authorities—through guidelines like ICH Q10/Q12 and agency-specific requirements—are harmonising expectations for process governance and knowledge management. Pharma regulatory consultants, leveraging cross-industry insights, play an essential role in navigating the modern RA landscape and optimising team structures for both compliance and innovation.

Ultimately, the ideal RA organisational model is one that:

• Supports efficient submissions and lifecycle management globally
• Ensures knowledge integration across disciplines and geographies
• Maintains audit-ready documentation flows and clear responsibilities
• Adapts dynamically to evolving product, portfolio, and regulatory challenges

Leveraging RA operating models tailored to company strategy and global regulatory governance requirements positions organisations to navigate regulatory challenges, avoid common pitfalls, and deliver therapeutic innovations safely and compliantly to patients worldwide.